and Media

News Releases

Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals® (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the Goldman Sachs 37th Annual Healthcare Conference on Tuesday, June 7, 2016, at 1:20 p.m. Pacific Time in Rancho Palos Verdes, Calif.

The presentation will be webcast live and available for replay from Portola's website at in the Investor Relations section.

About Portola Pharmaceuticals, Inc. 

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; ANDEXXA™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit and follow the Company on Twitter @Portola_Pharma.


Investor Contact:
Ana KaporPortola

Media Contact:
Julie NormartW2O

Primary Logo

Portola Pharmaceuticals, Inc.